Northern Trust Corp Sells 5,230 Shares of Astera Labs, Inc. $ALAB

Key Points

• Northern Trust Corp reduced its stake in Astera Labs by 1.8%, owning approximately 290,890 shares valued at about $17.4 million after selling 5,230 shares in Q1.
• Wall Street analysts have boosted their target prices for Astera Labs, with Evercore ISI increasing it from $104 to $215, reflecting a positive outlook as the stock currently holds a consensus rating of "Moderate Buy."
• Insiders, including the COO and CFO, sold a significant amount of shares, totaling approximately $64.7 million, with the COO reducing his stake by 4.82% and the CFO by 16.16%.

Northern Trust Corp lowered its stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 1.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,890 shares of the company's stock after selling 5,230 shares during the period. Northern Trust Corp owned about 0.18% of Astera Labs worth $17,357,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Astera Labs by 2,824.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company's stock valued at $20,467,000 after acquiring an additional 149,240 shares in the last quarter. Aigen Investment Management LP lifted its stake in shares of Astera Labs by 50.9% in the 1st quarter. Aigen Investment Management LP now owns 17,920 shares of the company's stock worth $1,069,000 after acquiring an additional 6,045 shares during the period. Pacific Point Advisors LLC raised its stake in shares of Astera Labs by 75.0% during the 1st quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company's stock worth $418,000 after buying an additional 3,000 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Astera Labs by 73.6% in the first quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company's stock valued at $954,000 after acquiring an additional 6,783 shares during the period. Finally, Taylor Frigon Capital Management LLC purchased a new stake in Astera Labs during the first quarter worth about $1,887,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Astera Labs

In other news, CFO Michael Truett Tate sold 100,000 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the completion of the sale, the chief financial officer directly owned 518,996 shares of the company's stock, valued at $88,945,534.48. This trade represents a 16.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jitendra Mohan sold 152,517 shares of Astera Labs stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $170.33, for a total value of $25,978,220.61. Following the completion of the transaction, the chief executive officer directly owned 450,001 shares in the company, valued at $76,648,670.33. This represents a 25.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,649,489 shares of company stock valued at $232,463,986 in the last quarter. Insiders own 12.50% of the company's stock.

Astera Labs Stock Up 6.4%

ALAB stock traded up $11.34 during trading on Thursday, reaching $187.95. 7,043,822 shares of the company's stock were exchanged, compared to its average volume of 4,935,493. The firm has a market cap of $31.24 billion, a PE ratio of 335.63, a P/E/G ratio of 4.62 and a beta of 1.48. The company's fifty day moving average price is $137.83 and its 200-day moving average price is $97.51. Astera Labs, Inc. has a 1-year low of $36.85 and a 1-year high of $199.47.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.11. The company had revenue of $191.93 million during the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business's revenue for the quarter was up 149.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, sell-side analysts expect that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ALAB. Susquehanna raised their price target on Astera Labs from $80.00 to $125.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Barclays reiterated an "overweight" rating and issued a $155.00 target price (up from $75.00) on shares of Astera Labs in a research note on Thursday, August 7th. Stifel Nicolaus set a $145.00 price target on Astera Labs and gave the company a "buy" rating in a research report on Monday, August 4th. William Blair initiated coverage on Astera Labs in a research note on Thursday, May 22nd. They set an "outperform" rating on the stock. Finally, Morgan Stanley raised their price target on shares of Astera Labs from $155.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $142.00.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.